Telomir Pharmaceuticals reports reversal of oxidative stress
Telomir Pharmaceuticals , Inc. (NASDAQ:TELO), a $141 million market cap biopharmaceutical company engaged in age-reversal science, has announced significant preclinical study results today, indicating ...
Telomir touts potential of Telomir-1 in addressing oxidative stress
Telomir Pharmaceuticals (NASDAQ:TELO) on Tuesday announced results from recent preclinical studies demonstrating the ability of Telomir-1 to fully reverse oxidative stress in human cell lines. Telomir ...
Medscape1mon
Genetic Basis of Drug Metabolism
In addition, the treatment for drug-induced oxidative hemolytic anemia is merely cessation of drug administration, with blood transfusion and corticosteroid administration warranted in severe cases.
Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa
A drug that receives Fast Track designation may benefit from more frequent interactions with the FDA throughout drug development. In addition, the Fast Track program allows for Accelerated Approval ...
ophthalmologytimes7d
FDA grants fast track designation to N-acetylcysteine amide tablets from Nacuity Pharmaceuticals
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with ...
News Medical on MSN4d
Study highlights novel approaches to treating diabetic cardiomyopathy
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and ...